Floatz logo

Rapamycin

Severe Combined Immune Deficiency (SCID)

National Institute of Allergy and Infectious Diseases (NIAID)Phase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Severe Combined Immune Deficiency (SCID) cohort.

Asset / SponsorPhaseRating
Fludarabine
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2/3BB
FILGRASTIM
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2BB
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Washington University School of Medicine
Phase 2/3BB
Busulphan
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2/3BB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 2/3BB

View all 34 →

Same molecule, other indications

Rapamycin is also rated in:

tuberous sclerosisDormant
BBB
Indicative ·
73 / 100
View asset →
disease related to transplantationDormant
BBB
Indicative ·
72 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →